medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2013, Number 4

<< Back Next >>

Ann Hepatol 2013; 12 (4)

Efficacy and safety of interferon-based therapy in the treatment of adult thalassemic patients with chronic hepatitis C: a 12 years audit

Vafiadis I, Trilianos P, Vlachogiannakos J, Karagiorga M, Hatziliami A, Voskaridou E, Ladas SD

Language: English
References: 32
Page: 364-370
PDF size: 469.44 Kb.


ABSTRACT

Background. HCV infection and transfusional iron overload in Thalassemic patients may result in liver disease. HCV treatment in Thalassemia has raised safety concerns. Aim. Estimate effectiveness and tolerability of interferon-based therapy in HCV-infected Thalassemic patients. Material and methods. Over a 12-year period, consecutive patients with β Thalassemia major (TM) and chronic hepatitis C received treatment. Liver biopsy, HCV-RNA and genotyping were performed beforehand. Sustained virological response (SVR) was defined as negative HCV-RNA 6 months post-treatment. Forty eight patients (26 M-22 F, mean age 39.8) were enrolled. Twenty nine patients were treated with conventional interferon alpha (IFNa) for 48 weeks (group A). Nineteen patients (10 naïve-9 previously IFNa experienced) received pegylated interferon (PEGIFN) (group B). Results. HCV-1 was found in 44%, HCV-2 in 14%, HCV-3 in 23% and HCV-4 in 19%. Group A: ten patients (38.5%) achieved SVR, 2 (7.5%) relapsed and 17 (54%) were non responders. Group B: five (28%) achieved SVR, 8 (44%) relapsed and 6 (28%) never responded. High HCV-RNA levels, genotype 1 and advanced liver fibrosis were independently associated with no response. Four patients (3 treated with IFN α, 1 with PEG-IFN) had to discontinue treatment due to complications. Conclusions. The response rate of IFN monotherapy in multi-transfused, HCV-infected Thalassemic patients is not inferior to that in nonmulti- transfused patients. IFNa administration is well-tolerated and should be recommended as initial treatment schedule in this setting.


REFERENCES

  1. Alter MJ. Epidemiology of hepatitis C infection. World J Gastroenterol 2007; 13: 2436-41.

  2. Angelucci E. Antibodies to hepatitis C virus in Thalassemia. Haematologica 1994; 79: 353-5.

  3. Vafiadis I, Voskaridou E, Delladetsima J, et al. Hepatitis C in Thalassemic patients effect of Interferon. FEMS Symposium, Instambul, June 29-July 1 1993. OP 36, p36.

  4. Christofidou M, Lambropoulou-Karatza C, Dimitracopoulos G, Spiliopoulou I. Distribution of hepatitis C virus genotypes in viremic patients with beta-Thalassemia. Eur J Clin Microbiol Infect Dis 2000; 19: 728-30.

  5. Syriopoulou V, Daikos GL, Kostaridou SL, Manolaki N, Nakopoulou L, Kattamis A, Kattamis C. Sustained response to interferon a-2a in Thalassemic patients with chronic hepatitis C. A prospective 8-year follow-up study. Haematologica 2005; 90: 129-31.

  6. Prati D, Zanella A, Farma E, De Mattei C, Bosoni P, Zappa M, Picone A, et al. A multicenter, prospective study on the risk of acquiring liver disease in anti-hepatitis C virus negative patients affected from homozygous β-Thalassemia. Blood 1998; 92: 3460-4.

  7. Di Marco V, Capra M, Gagliardotto F, Borsellino Z, Cabibi D, Barbaria F, Ferraro D, et al. Liver disease in chelated transfusion-dependent Thalassemics: the role of iron overload and chronic hepatitis C. Haematologica 2008; 93: 1243-6.

  8. Poynard T, McHutchison J, Manns M, Trepo C, Lindsay K, Goodman Z, Ling MH, et al. Impact of Pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 2002; 122: 1303-13.

  9. Singal AK, Singh A, Jaganmohan S, Guturu P, Mummadi R, Kuo YF, Sood GK. Antiviral therapy reduces risk of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis. Clin Gastroenterol Hepatol 2010; 8: 192-9.

  10. Ghany MG, Strader DB, Thomas DL. Diagnosis, management and treatment of hepatitis C: An update. Hepatology 2009; 49: 1335-74.

  11. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-64.

  12. Saffar MJ, Saffar H, Khalilian AR, Naqshvar F. Combination therapy with interferon and ribavirin for chronic hepatitis C infection in beta-Thalassemia major. East Mediterr Health J 2009; 15: 785-91.

  13. Sood A, Sobti P, Midha V, Singla D, Kaur A, Kaushal S, Sood N, et al. Efficacy and safety of pegylated IFN alfa 2b alone or in combination with ribavirin in Thalassemia major with chronic hepatitis C. Indian J Gastroenterol 2010; 29: 62-5.

  14. Telfer PT, Garson JA, Whitby K, Grant PR, Yardumian A, Hoffbrand AV, Wonke B. Combination therapy with interferon alpha and ribavirin for chronic hepatitis C virus infection in Thalassemic patients. Br J Haematol 1997; 98: 850-5.

  15. Li CK, Chan PK, Ling SC. Interferon and ribavirin as frontline treatment for chronic hepatitis C infection in Thalassemia major. Br J Haematol 2002; 117: 755-8.

  16. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, Frau MR, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with Thalassemia major and chronic hepatitis C. J Pediatr 1994; 125: 123-8.

  17. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon a therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410-5.

  18. Olynyk JK, Reddy KR, Di Bisceglie AM, Jeffers LJ, Parker TI, Radick JL, Schiff ER, et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-9.

  19. Sievert W, Pianko S, Warner S, Bowden S, Simpson I, Bowden D, Locarnini S. Hepatic iron overload does not prevent a sustained virological response to interferon-α therapy: a long term follow-up study in hepatitis C-infected patients with β Thalassemia major. Am J Gastroenterol 2002; 97: 982-7.

  20. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.

  21. Angelucci E, Pilo F. Treatment of hepatitis C in patients with Thalassemia. Haematologica 2008; 93: 1121-3.

  22. Angelucci E, Muretto P, Nicolucci A, Baronciani D, Erer B, Gaziev J, Ripalti M, et al. Effects of iron overload and hepatitis C virus positivity in determining progression of liver fibrosis in Thalassemia following bone marrow transplantation. Blood 2002; 100: 17-21.

  23. Alavian SM, Tabatabaei SV. Treatment of chronic hepatitis C in polytransfused Thalassemic patients: a meta-analysis. J Viral Hepat 2010; 17: 236-44.

  24. Inati A , Taher A , Ghorra S , Koussa S , Taha M , Aoun E , Sharara AI. Efficacy and tolerability of Peginterferon alpha- 2a with or without ribavirin in Thalassemia major patients with chronic hepatitis C virus infection. Br J Haematol 2005; 130: 644-6.

  25. Kountouras D, Koskinas J, Berdoussi H, et al. Efficacy and safety of PEG-IFN alpha-2b treatment for 48 weeks in adult Thalassemic patients with chronic HCV infection. J Hepatol 2007; 46: S190-S191.

  26. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, Häussinger D, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 975-82.

  27. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P, Ramadori G, et al. Transfusion immunomodulation or TRIM: what does it mean clinically? Hematology 2005; 10(Suppl. 1): 208-14.

  28. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon- alfa2a and ribavirin combination therapy in chronic hepatitis C: a randomized of treatment duration and ribavirin dose. Ann Intern Med 2004; 140: 346-55.

  29. Alavian SM, Tabatabaei SV. Therapy of hepatitis C in Thalassemia: the influence of iron on achieving sustained viral response. Ann Hematol 2010; 89: 215-6.

  30. Griffiths A, Olynyk JK. Iron and the response to treatment of hepatitis C. Am J Gastroenterol 2002; 97: 788-90.

  31. Kamal SM, Fouly AH, Mohamed MK, Hochnikos BW, Lamont FT, Gohary IS, Koziel MJ. Peginterferon alpha-2b therapy with and without ribavirin in patients with Thalassemia: a randomized study. J Hepatol 2006; 44: S217.

  32. Harmatz P, Jonas MM, Kwiatkowski JL, Wright EC, Fischer R, Vichinsky E, Giardina PJ, et al. Safety and efficacy of pegylated interferon alpha-2a and ribavirin for the treatment of hepatitis C in patients with Thalassemia. Haematologica 2008; 93: 1247-51.




2020     |     www.medigraphic.com